The effect of menopausal hormone therapy on gastrointestinal cancer risk and mortality in South Korea: a population-based cohort study

Table 3 Hazard ratios^a for mortality: multivariate analyses

Outcome variables	MHT users		Non-users		HR	95% CI	P
Outcome variables	n	Rate^b	n	Rate^b	HR	95% CI	P
All-cause mortality	333	0.238	2173	0.314	0.784	0.698, 0.880	< .0001
Cancer-related mortality	115	0.082	661	0.096	0.874	0.717, 1.066	0.1843
Mortality from GI cancer	50	0.036	338	0.049	0.737	0.547, 0.993	0.0445
Gastric	7	0.005	86	0.012	0.411	0.190, 0.890	0.0240
Colorectal	3	0.002	81	0.012	0.181	0.057, 0.572	0.0036
Hepatobiliary	26	0.019	121	0.018	1.077	0.704, 1.647	0.7332
Pancreatic	13	0.009	48	0.007	1.333	0.721, 2.463	0.3598

Other covariates (age group, income, region, Charlson comorbidity index, and year of study entry) were adjusted in each survival analysis
CI confidence interval, GI gastrointestinal, HR hazard ratio, MHT menopausal hormone therapy
^aAdjusted hazard ratios for mortality in MHT users compared to non-users
^bMortality rates per 100,000 person-years

ISSN: 1471-230X